BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.

CONCLUSIONS: We recommend BRCA testing to all Chinese OC patients and those general Chinese who have family members with hereditary breast and ovarian related cancer (HBOC)-related cancers. Variants carriers would not only benefit from early prevention of OC but also for the medical management. PMID: 30078507 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30078507?dopt=Abstract

Source: Gynecologic Oncology - August 2, 2018 Category: Cancer & Oncology Authors: Li A, Xie R, Zhi Q, Deng Y, Wu Y, Li W, Yang L, Jiao Z, Luo J, Zi Y, Sun G, Zhang J, Shi Y, Liu J Tags: Gynecol Oncol Source Type: research